• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伴有ALK重排的多原发性肺癌：一例报告及文献综述

Multiple Primary Lung Cancers With ALK Rearrangement: A Case Report and Literature Review.

作者信息

Huimin Zhou, Xueting Wang, Qi Qi, Lingxin Feng, Xue Yang, Zhuang Yu, Jing Wang

机构信息

Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.

出版信息

Front Oncol. 2022 May 23;12:897451. doi: 10.3389/fonc.2022.897451. eCollection 2022.

DOI:10.3389/fonc.2022.897451
PMID:35677159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9168597/
Abstract

Multiple primary lung cancers (MPLCs) are that patients with lung cancer may present with two primary tumors at the same time (synchronous multiple primary lung cancer, SMPLC) or may develop a second, metachronous primary lung cancer after treatment of the initial lesion. Currently, there are no definitive guidelines for the diagnosis and treatment of multiple primary lung cancers. Herein, we report a case of double primary lung cancers with ALK rearrangement. The patient was treated with chemotherapy, targeted therapy, and radiotherapy. After these treatments, the patient was free of locally recurrent or distant disease at 2 years.

摘要

多发性原发性肺癌是指肺癌患者可能同时出现两个原发性肿瘤（同时性多发性原发性肺癌，SMPLC），或者在初始病灶治疗后可能发生第二个异时性原发性肺癌。目前，对于多发性原发性肺癌的诊断和治疗尚无明确的指南。在此，我们报告一例伴有ALK重排的双原发性肺癌病例。该患者接受了化疗、靶向治疗和放疗。经过这些治疗后，患者在2年时无局部复发或远处疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/828c7e7d0ef9/fonc-12-897451-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/d83da9be6023/fonc-12-897451-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/62fdabb058e1/fonc-12-897451-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/feea94925125/fonc-12-897451-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/82deebeac31f/fonc-12-897451-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/477322ad6a89/fonc-12-897451-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/7b5b43219733/fonc-12-897451-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/828c7e7d0ef9/fonc-12-897451-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/d83da9be6023/fonc-12-897451-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/62fdabb058e1/fonc-12-897451-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/feea94925125/fonc-12-897451-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/82deebeac31f/fonc-12-897451-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/477322ad6a89/fonc-12-897451-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/7b5b43219733/fonc-12-897451-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2a/9168597/828c7e7d0ef9/fonc-12-897451-g007.jpg

相似文献

1
Multiple Primary Lung Cancers With ALK Rearrangement: A Case Report and Literature Review.伴有ALK重排的多原发性肺癌：一例报告及文献综述
Front Oncol. 2022 May 23;12:897451. doi: 10.3389/fonc.2022.897451. eCollection 2022.
2
A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib.一例携带表皮生长因子受体突变和间变性淋巴瘤激酶重排的同步性多原发性肺腺癌患者经奥希替尼和阿来替尼联合治疗成功治愈。
Respir Med Case Rep. 2021 Apr 13;33:101418. doi: 10.1016/j.rmcr.2021.101418. eCollection 2021.
3
Synchronous Primary Lung Cancers Containing Discrete Driver Mutations in a Never-Smoker: Case Report.从不吸烟者中含有离散驱动基因突变的同步原发性肺癌：病例报告
Case Rep Oncol. 2023 Nov 14;16(1):1384-1389. doi: 10.1159/000533892. eCollection 2023 Jan-Dec.
4
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.治疗间变性淋巴瘤激酶重排非小细胞肺癌脑转移
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
5
Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.ALK 重排的晚期肺腺癌患者在克唑替尼治疗期间行手术切除的同时性原发性子宫癌。
Transl Lung Cancer Res. 2016 Feb;5(1):145-9. doi: 10.3978/j.issn.2218-6751.2016.01.04.
6
Metachronous and Synchronous Triple Primary Lung Cancers in a Chronic Smoker.一名慢性吸烟者的异时性和同时性三原发性肺癌
J Community Hosp Intern Med Perspect. 2024 Mar 4;14(2):100-103. doi: 10.55729/2000-9666.1322. eCollection 2024.
7
Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis.一名长期存活的间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌伴软脑膜癌转移患者接受四线ALK抑制剂治疗及脑部放疗的情况
Anticancer Drugs. 2019 Feb;30(2):201-204. doi: 10.1097/CAD.0000000000000699.
8
Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
Diagn Cytopathol. 2018 Sep;46(9):744-747. doi: 10.1002/dc.23936. Epub 2018 Apr 10.
9
Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.肺癌中的间变性淋巴瘤激酶重排：其生物学及临床意义
Respir Investig. 2014 Nov;52(6):330-8. doi: 10.1016/j.resinv.2014.06.005. Epub 2014 Jul 30.
10
[Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].[晚期ALK阳性非小细胞肺癌治疗的全程管理：一例报告]
Zhongguo Fei Ai Za Zhi. 2021 Aug 20;24(8):598-604. doi: 10.3779/j.issn.1009-3419.2021.101.32. Epub 2021 Aug 4.

本文引用的文献

1
Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.晚期 NSCLC 患者脑转移的预测性驱动基因：EGFR、ALK 和 RET 基因突变。
Cancer Med. 2020 Jan;9(2):487-495. doi: 10.1002/cam4.2706. Epub 2019 Nov 25.
2
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).针对间变性淋巴瘤激酶（ALK）的药物发现。
J Med Chem. 2019 Dec 26;62(24):10927-10954. doi: 10.1021/acs.jmedchem.9b00446. Epub 2019 Aug 26.
3
ALK Inhibitors in the Treatment of ALK Positive NSCLC.
ALK抑制剂在ALK阳性非小细胞肺癌治疗中的应用
Front Oncol. 2019 Jan 9;8:557. doi: 10.3389/fonc.2018.00557. eCollection 2018.
4
Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options.肺癌脑转移：分子机制与治疗选择。
Cell Oncol (Dordr). 2017 Oct;40(5):419-441. doi: 10.1007/s13402-017-0345-5. Epub 2017 Sep 18.
5
Clinical implications of genetic heterogeneity in multifocal pulmonary adenocarcinomas.多灶性肺腺癌中基因异质性的临床意义
J Thorac Dis. 2016 Dec;8(12):E1734-E1738. doi: 10.21037/jtd.2016.12.06.
6
Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes.肺癌脑转移：构建分子和系统层面的理解以改善治疗结果。
Int J Biochem Cell Biol. 2016 Sep;78:288-296. doi: 10.1016/j.biocel.2016.07.025. Epub 2016 Jul 27.
7
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.NCCN指南解读：非小细胞肺癌，2016年第4版
J Natl Compr Canc Netw. 2016 Mar;14(3):255-64. doi: 10.6004/jnccn.2016.0031.
8
Surgical treatment for synchronous primary lung adenocarcinomas.同步性原发性肺腺癌的外科治疗
Ann Thorac Surg. 2014 Dec;98(6):1983-8. doi: 10.1016/j.athoracsur.2014.07.006. Epub 2014 Oct 22.
9
The 2015 WHO classification of lung tumors.2015年世界卫生组织肺肿瘤分类
Pathologe. 2014 Nov;35 Suppl 2:188. doi: 10.1007/s00292-014-1974-3.
10
Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer?肺叶切除术在第二原发性肺癌的外科治疗中真的比亚肺叶切除术更有效吗？
Eur J Cardiothorac Surg. 2013 Aug;44(2):e120-5; discussion e125. doi: 10.1093/ejcts/ezt219. Epub 2013 May 8.